News headlines about Proteon Therapeutics (NASDAQ:PRTO) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.280443929856 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of analysts recently weighed in on PRTO shares. Zacks Investment Research downgraded Proteon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 17th. Maxim Group set a $6.00 target price on Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Finally, HC Wainwright set a $2.00 target price on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.00.
Proteon Therapeutics (NASDAQ PRTO) opened at 1.35 on Monday. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45. The stock’s market capitalization is $23.79 million. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.52.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.11. On average, equities research analysts predict that Proteon Therapeutics will post ($1.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://stocknewstimes.com/2017/08/21/proteon-therapeutics-prto-earns-news-impact-score-of-0-18.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
